Risdiplam Sales Forecast Summary

Key Factors Driving Risdiplam Growth

Market Share Gains and New Patient Starts

• Risdiplam (Evrysdi) has carved out a leading position in the spinal muscular atrophy (SMA) treatment landscape as the first and only small-molecule, orally administered SMN2 splicing modifier approved globally, contributing to strong uptake in patient populations across ages and disease severities.
• The drug’s home-based daily oral dosing has helped broaden patient starts compared with therapies requiring injections or gene therapy infusions, particularly outside specialized infusion centers.
• Evrysdi’s global reach — with approval in more than 100 countries and thousands of treated patients — reflects continuous new patient starts driven by expanded diagnosis and treatment adoption.
• Favorable clinical profiles and real-world evidence of motor function benefits in infants, children, and adults have supported sustained increases in patient initiations.

Expansion Across Key Indications

• Spinal Muscular Atrophy (SMA): Risdiplam is approved to treat patients with 5q SMA, including type 1, type 2, and type 3, across a broad age range starting from infants (≥2 months) to adults.
• The mechanism increases the production of functional SMN (survival motor neuron) protein, targeting the underlying genetic cause of SMA and slowing disease progression.
• Expanded formulations, such as the recently approved tablet formulation, enhance convenience and may further support uptake across age groups able to swallow pills, beyond the traditional oral liquid solution.
• Ongoing clinical and real-world studies continue to evaluate efficacy in various SMA subpopulations, including pre-symptomatic infants and older adults, signaling future opportunities for refined indications.

Geographic Expansion

• Risdiplam (Evrysdi) has global regulatory approvals, including in the United States, European Union, Japan, Canada, Australia, Brazil, and many other countries.
• The approval of room-temperature stable tablets in both the US and Europe expands geographic reach by addressing logistical and adherence challenges in diverse markets.
• Generics and patent challenges (e.g., rulings in India allowing generic manufacturing) are reshaping access in emerging markets, potentially broadening geographic penetration and treatment availability.
• Local partnerships with healthcare systems and reimbursement frameworks in major regions support differentiated access strategies.

New Indication Approvals

• Recent regulatory approvals include the tablet formulation indication, offering patients a new, convenient dosage form with the same efficacy and safety profile as the oral solution.
• Some countries have also approved risdiplam for pre-symptomatic SMA and adjusted dosing for very young infants, broadening its use to earlier treatment windows.
• The expanded label supports broader patient eligibility and earlier intervention, which can improve clinical outcomes.

Strong Volume Momentum

• Evrysdi has demonstrated strong and sustained growth, with worldwide sales increasing year-over-year and reaching near blockbuster levels (e.g., ~CHF 1.6 billion / ~$1.8 billion in 2024).
• Growth is supported by rising diagnosis rates, increased physician confidence in oral therapy, and continued favorable clinical outcomes across SMA types.
• Risdiplam’s position as a preferred oral therapy in markets where injectable or infusion treatments pose greater barriers contributes to momentum in patient volumes.
• Forecasts suggest continued strong sales growth toward 2030 (e.g., projected to approach ~$2.9 billion by 2031 for Evrysdi), reflecting robust market demand.

Competitive Differentiation and Market Trends

• Risdiplam’s oral small-molecule profile differentiates it from competitors like intrathecal antisense oligonucleotide therapies and single-dose gene therapies, offering home administration and broader eligibility.
• Ease of dosing and the ability to reach central and peripheral tissues enhance its clinical value in preserving motor function across ages.
• Broader trends toward earlier diagnosis and treatment access (including expanded newborn and genetic screening) support greater adoption.
• Payor and healthcare system trends in value-based care and long-term outcomes are increasingly recognizing the practical advantages of daily oral therapies like risdiplam in SMA treatment strategies.

Risdiplam Recent Developments

• FDA Approves Risdiplam Tablet (2025): The US Food and Drug Administration approved a 5 mg risdiplam tablet, providing a new non-refrigerated, orally administered formulation for people aged ≥2 years who weigh at least 44 lb (20 kg). This expands convenience and flexibility versus the original oral solution.
• European Commission Tablet Approval (2025): The European Commission also approved a room-temperature stable tablet formulation of Evrysdi, broadening the product’s label and expected uptake in Europe.
• Expanded Indications in Japan (2024): Japan’s Ministry of Health, Labour and Welfare approved additional indications and dosages for pre-symptomatic SMA and very young infants under 2 months, enabling earlier treatment after genetic diagnosis.
• Global Use Milestones (2025): Evrysdi is approved in 100+ countries worldwide, with more than ~16,000 patients treated, underscoring broad global adoption.

“Risdiplam Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Risdiplam for approved indication like Spinal muscular atrophy in the 7MM. A detailed picture of Risdiplam’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Risdiplam for approved indications. The Risdiplam market report provides insights about Risdiplam’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Risdiplam performance, future market assessments inclusive of the Risdiplam market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Risdiplam sales forecasts, along with factors driving its market.

Risdiplam Drug Summary

Risdiplam, sold under the brand name Evrysdi, is an oral survival motor neuron 2 (SMN2) pre-mRNA splicing modifier approved for treating spinal muscular atrophy (SMA) in patients aged 2 months and older, including types 1, 2, and 3 caused by mutations in the SMN1 gene on chromosome 5q that result in SMN protein deficiency. As a small-molecule pyridazine derivative, it binds to SMN2 pre-mRNA to promote inclusion of exon 7 during splicing, thereby increasing production of full-length, functional SMN protein throughout the central nervous system and peripheral tissues to support motor neuron survival, improve muscle strength, and slow disease progression. Administered once daily as an oral solution (dosed by weight, e.g., 0.15 mg/kg for those <20 kg or 0.25 mg/kg for ≥20 kg), it offers at-home convenience compared to intrathecal alternatives like nusinersen, with clinical trials (FIREFISH, SUNFISH, JEWELFISH) demonstrating sustained SMN protein increases and motor function gains across SMA severities. The report provides Risdiplam’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Risdiplam Market Report 

The report provides insights into:

• A comprehensive product overview including the Risdiplam MoA, description, dosage and administration, research and development activities in approved indication like Spinal muscular atrophy.
• Elaborated details on Risdiplam regulatory milestones and other development activities have been provided in Risdiplam market report.
• The report also highlights Risdiplam‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan. 
• The Risdiplam market report also covers the patents information, generic entry and impact on cost cut.
• The Risdiplam market report contains current and forecasted Risdiplam sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Risdiplam market report also features the SWOT analysis with analyst views for Risdiplam in approved indications.

Methodology

The Risdiplam market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Risdiplam Analytical Perspective by DelveInsight

In-depth Risdiplam Market Assessment

• This Risdiplam sales market forecast report provides a detailed market assessment of Risdiplam for approved indication like Spinal muscular atrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Risdiplam sales data uptil 2034.

Risdiplam Clinical Assessment

• The Risdiplam market report provides the clinical trials information of Risdiplam for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

Risdiplam Competitive Landscape

• The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Risdiplam Market Potential & Revenue Forecast

• Projected market size for the Risdiplam and its key indications
• Estimated Risdiplam sales potential (Risdiplam peak sales forecasts)
• Risdiplam Pricing strategies and reimbursement landscape

Risdiplam Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Risdiplam Market positioning compared to existing treatments
• Risdiplam Strengths & weaknesses relative to competitors

Risdiplam Regulatory & Commercial Milestones

• Risdiplam Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Risdiplam Clinical Differentiation

• Risdiplam Efficacy & safety advantages over existing drugs
• Risdiplam Unique selling points 

Risdiplam Market Report Highlights 

• In the coming years, the Risdiplam market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Risdiplam companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Risdiplam’s dominance.
• Other emerging products for Spinal muscular atrophy are expected to give tough market competition to Risdiplam and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Risdiplam in approved indications.
• Analyse Risdiplam cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Risdiplam sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Risdiplam in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Risdiplam? How strong is Risdiplam’s clinical and commercial performance?
• What is Risdiplam’s clinical trial status in each individual indications such as Spinal muscular atrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Risdiplam Manufacturers?
• What are the key designations that have been granted to Risdiplam for approved indications? How are they going to impact Risdiplam’s penetration in various geographies?
• What is the current and forecasted Risdiplam market scenario for approved indications? What are the key assumptions behind the forecast? 
• What are the current and forecasted sales of Risdiplam in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to Risdiplam for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is Risdiplam? What is the duration of therapy and what are the geographical variations in cost per patient?